Atlantic Bridge’s Post

Corify Care, the medical technology company that is transforming the diagnosis and treatment of cardiac arrhythmias, has announced the closing of a €3 million financing round advised by the firm RCD and led by Clave-Mondragon, along with obtaining public grants for a further €3 million. In this article, the words of Andreu M. Climent, CEO of Corify Care. The RCD team has been led by Antoni Rosselló Rofes, partner in the innovation and entrepreneurship area. #IberianLawyer #operation #medicaltechnology #lawfirm #lawyers Read the full article -->https://lnkd.in/dHxQV9jD

We are pleased and honored to announce that the Tokio based Kaneka corporation, has aquired EndoStream Medical Ltd., marking the first and very successful exit for Galil Ofek Innovation Fund. EndoStream, specializes in innovative technologies for cerebrovascular diseases and has developed the Nautilus™ device for treating cerebral aneurysms. This acquisition underscores the strength of Israel's medical device sector and the value of our investment strategy. This milestone reflects GO Innovation commitment to nurturing groundbreaking medical technologies that address critical healthcare needs. Danel Mayer Israel Innovation Authority Eyal Aviram EndoStream Medical

We are delighted to share that Xinzeyuan, a leading platform in the minimally invasive surgical supply chain and a portfolio company of Qiming Venture Partners, has successfully completed its B+ round of financing, raising nearly RMB 100 million. Qiming Venture Partners has led in the Series B round and continued to invest in this round. The company has secured two rounds of financing within just six months, reflecting strong recognition and confidence from investment institutions. Founded in 2015, Xinzeyuan has built a robust platform centered on the full supply chain of minimally invasive medical devices. Its core business spans four key areas: rigid endoscopes, flexible endoscopes, endoscopic surgical devices, and minimally invasive surgical devices, serving a wide range of medical brands. Oscar Zhang, Partner of Qiming Venture Partners, said, "In the six months since we led Xinzeyuan's Series B round, the company has made significant strides in product development and business expansion. We have been continually impressed by Xinzeyuan's innovation and execution. We remain confident in the future of China's medical device industry and are committed to supporting exceptional companies like Xinzeyuan as they grow and make their mark on the global stage." #InnovationInHealthcare #MinimallyInvasiveSurgery #MedicalDevices #VentureCapital #MedTechLeadership #QimingPortfolio #QimingHealthcare

Big News in MedTech! Expanse Medical is thrilled to announce that Jeff Hopkins has joined FlowPhysix, our spin-off company, as the new CEO and a member of the Board of Directors. With over 30 years in the medical device industry, Jeff's track record in innovation and growth is legendary. From Horizon Medical Products to Acclarent, he has led multiple companies to success, shaping the landscape of medical technology. Having worked with Jeff in the past, I have firsthand experience of his impactful leadership. FlowPhysix, formerly known as Expanse ICE, is poised to revolutionize the vascular market with its newly named FLOWRUNNER™ Aspiration System. With FDA clearance and strong clinical outcomes, we are ready for commercial launch. Jeff's proven leadership and commercialization acumen are exactly what we need during this exciting time of transformation and growth. Jeff Hopkins shares our vision of transforming treatments for vascular diseases. Under his guidance, we anticipate rapid adoption and enhanced patient outcomes worldwide. As Jeff says, "FLOWRUNNER will set new standards of care for clot removal, creating a new category of aspiration that works as physics intended." This solution will undoubtedly be a challenge to Inari and Pneumbra, pushing the boundaries of what's possible in the vascular market. To learn more about FlowPhysix and the innovative thrombectomy system, please visit our website flowphysix.com Congrats Jeff! Let's welcome Jeff aboard by commenting below. #MedTech #Innovation #Leadership

With the aim of driving investment outcomes, #AusMedtechInvest 2024 features presentations from 8 private and listed Australian medtechs, spanning early to late-stage, seeking partners to further commercialise their technology. Wellumio is great to be part of the #AusMedtechInvest and on the podium today! #AusBioInv #biggestweekinmedtech #AusMedtechInvest2024

Big news in Medtech! Merit Medical just made a bold $105M move, scooping up the EsophyX Z+ device from EndoGastric Solutions. This isn't just a win for Merit; it's a game-changer for those battling GERD. This smart addition is all about minimally invasive treatment, offering fresh hope and cutting-edge care without a single incision. With Merit Medical's focus on strategic growth, this deal isn't merely a purchase; it's a leap forward expanding their reach in gastrointestinal care. Thoughts on how this acquisition might change the playing field? Drop your take below! #Medtech #Innovation #HealthcareIndustry

We are proud to announce the successful closure of Kaminari Medical’s €3.8M funding round.   The round includes €2.3M in investments from Graduate Entrepreneur Fund, NLC Health Ventures, Libertatis Ergo Holding B.V. (Leiden University), and Demcon investment. Additionally, it was supported by a €1.5M Innovation Credit from the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland (RVO)).   Kaminari Medical uses intravascular imaging technology that leverages the power of photoacoustics and ultrasound to provide real-time qualification of plaque composition in CAD, particularly lipid-rich plaques that pose the greatest risk of rupture. This solution aims to deliver highly accurate assessments of coronary arteries to enable physicians to better assess the risk of major cardiovascular events, guide optimal treatment strategy, and save lives.   With this strategic investment, Kaminari Medical will accelerate the development of their technology platform, allowing them to initiate clinical trials and prepare for market introduction.   F.INSTITUTE acted as financial advisor for the transaction.   #MedTech #Innovation #VentureCapital

Belgian Firm Bedal Raises €10.2M for Catheter Securement Devices Exciting news in the medtech world! Diepenbeek-based Bedal International has successfully closed a €10.2M funding round to expand its innovative FlexGRIP catheter securement devices, enhancing patient care globally. This funding round, backed by prominent investors like White Fund, SFPIM, and notable US medtech investors, signifies strong confidence in Bedal's mission. Since its inception, Bedal has focused on developing securement solutions that prioritise patient comfort, addressing key challenges faced during intravenous catheter usage. The support from industry veterans and the recent appointment of Dr Steve Bierman as co-CEO promise a bright future for Bedal's growth and innovation. This new capital will accelerate Bedal's operational and commercial expansion, especially into the US market, further establishing FlexGRIP devices as a gold standard in catheter care. It's a thrilling chapter for Bedal, setting new benchmarks in medical devices with a profound impact on patients' lives. #Medtech #HealthcareInnovation #LifeSciences

I am really excited to see the Medtech progress in Mexico! 🇲🇽 Over the past three years, we've seen 61 medical device clinical trials, showcasing the country's growing role in global healthcare innovation. Here are some notable success stories: 1. fastwavemedical: Achieved successful 30-day results in their first-in-human study using advanced intravascular lithotripsy (IVL) technology at San Lucas Hospital, Chiapas. 📈 2. NuView Life Sciences, Inc : Planning to commence clinical trials for their NV-VPAC1 liquid biopsy diagnostic test in early 2024 in Guadalajara and Mexico City, with COFEPRIS approval anticipated in 2025. 🔬 3. neurocytonix-inc: Received regulatory acknowledgment from COFEPRIS for their cerebral palsy clinical trial on NCX-CP-01. 🧠 Comment below on what you think about the Medtech progress in Mexico! Happy to engage on a conversation. #Medtech #ClinicalTrials #NuView #NeuroCytonix #FastWave

🚨 Big News in Medical Tech 🚨 Route 92 Medical, a neurovascular interventional solutions company based in San Mateo, just raised $50M in Series F extension funding! 💰 Led by Novo Holdings, the round also included US Venture Partners, Norwest Venture Partners, InnovaHealth Partners, LP, and The Vertical Group. 🏦 In connection with the investment, Noel Jee, Partner, Growth Investments, Novo Holdings US, joins the Route 92 Board of Directors. 🎯 What’s Next? The funding will accelerate global commercialization of their neurovascular intervention portfolio and support regulatory approvals in new regions. 🌍 Why it Matters: With innovations like the FreeClimb, HiPoint Catheter Systems, and the Monopoint® Operating Platform—powered by the Tenzing® Delivery Catheter—Route 92 is simplifying stroke treatment by streamlining procedures, reducing time and cost, and improving outcomes. ⏱️💡 CEO Tony Chou emphasizes how this investment will help Route 92 continue collaborating with neurovascular clinicians to solve real-world challenges and deliver differentiated solutions for better patient care. 🏥 Noel Jee, Partner at Novo Holdings, joins the Board of Directors to further drive this mission forward. 📈 💼 Transforming neuro intervention, one innovation at a time! 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs #MedicalTech #Neurovascular #Funding #Innovation #Healthcare #Route92 #PatientCare #FutureTechly